anaemic CHF with ID of combination therapy by Mircera and Maltofer there was a significant increase Hb (to 9,8±0,7 g/dl to 12,8±0,6 g/dl) (p<0,01),a significant NYHA class from 3,4±0,2 to 2,2±0,3 (p<0,05), a longer endurance on exercise testing from 243±34 to 384±75 meters (p<0,01).There was also a significant fail in serrum NT pro BNP levels from 684±108 pg/ml to 239±81pg/ml (p<0,05).Combination therapy significant reduction in plasma creatinine (p<0,01) and an increase in estimated creatinine clearance (p=0,02). Concusion: Iv-iron administration improves iron status (increased TSAT and ferritin). Percutaneus Mircera in dose 50 IU in day in one mounth in follow-up 6 mounths has improve EPO disfunction.Combination therapy has emerged as a well tolerated and effective therapy to improve symptoms and quality of life in anemic CHF patients with ID. Therefore, combination therapy of EPO and iv-iron may best.
Background: Acute decompensated heart failure (ADHF) is a common and highly morbid cardiovascular disorder. Diuresis is a major therapy for the reduction of congestive symptoms. However, most diuretics cause hyponatremia, which is a worsening factor of prognosis of ADHF patients. The purpose of this study was to examine the efficacy and safety of tolvaptan, which is a selective vasopressin V2 receptor antagonist and produces water excretion without changes in sodium excretion, compared with carperitide. Methods and results: One hundred and nine hospitalized ADHF patients were enrolled and randomly assigned tolvaptan or carperitide treatment groups. We compared the efficacy and safety of these two drugs. Subjective symptoms and plasma BNP level were similarly improved by treatment in both groups. Blood pressure was significantly lower in the carperitide group than in the tolvaptan group after treatment (P<0.05). Urine volume was significantly higher in the tolvaptan group (P<0.01), but volume of water intake was also higher in the tolvaptan group (P<0.01). Adverse cardiac events such as worsening heart failure and hypotension requiring drug discontinuation were more frequent in the carperitide group (P=0.027). The average drug cost of tolvaptan was significantly lower than that of carperitide (P<0.001).
Conclusions:
The present study reveals that tolvaptan is a novel promising agent for ADHF in terms of efficacy, safety, and economy compared to carperitide.
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The impact of the carvedilol therapy on the chronic heart failure in children. Does it depend on the morphological deference of systemic ventricle?
H. Mori, S. Yasukouchi, K. Takigiku, S. Tazawa, Y. Odanaka. Nagano Children's Hospital, Nagano, Japan Background: There have been a few reports about the use of carvedilol in children with congenital heart disease (CHD) to treat chronic heart failure. Purpose: To examine the effectiveness of carvedilol for children with chronic heart failure including congenital heart disease.
[Subjects]32 patients admitted for heart failure were initiated carvedilol from January 1999 to December 2012. They consisted of 16 males and 16 females, with ages ranging from 1.8 years to 21.6 years (mediam age:5.3±6.0 years). Fourteen patients had congenital heart disease (hypoplastic left heart syndrome in 7 and other CHDs in 7). Heart failure occurred due to myocardial infarction in 6, cardiomyopathy in 7 and myocarditis in 5. The mean age when they were initiated carvedilol administration was 1.1±3.7 years (range:1 months to 13 years).The mean follow-up period was 3.3±3.6 years (range:1.1 years to 13.5 years). Methods: To evaluate the efficacy of carvedilol therapy quantitatively, we use these parameters: cardiothoracic ratio (CTR), b-type natriuretic peptide (BNP), fractional area change (FAC), Tei index,of systolic ventricle, and the early diastolic velocity at the mitral annulus (e'). We devided the patients into two groups.
In group A, The patients have systemic right ventricule, while in group B, the patients have systemic left ventricle. We compared the parameters between two groups before initiation of carvedilol and at the end of the flollow-up period. Moreover, we compared the difference of the change of these parameters in each group. [Results] In both groups,CTR,BNP and Tei index were decreased significantly (CTR:A 55±5% vs. 50±5%,p<0.01, B 59±6% vs. 51±6%,p<0.001; mean BNP:A 251±335pg/ml vs. 26±24pg/ml p<0.01,B 286±781pg/ml vs. 26±153pg/ml p<0.01, Tei:A 0.65±0.13 vs. 0.44±0.11 p<0.01,B 0.59±0.15 vs. 0.31±0.10 p<0.001). FAC is also improved significantly in both groups (A 0.27±0.07 vs. 0.34±0.05, p<0.01,B 0.21±0.08 vs. 0.36±0.07, p<0.001). But e' is not changed significantly during this period (A 6.0±4.2cm/s vs. 7.2±2.3cm/s, B 5.9±2.9cm/s vs. 11.0±3.9cm/s). Then, there was no significant difference in the change of each parameters between two groups. Conclusions: Carvedilol therapy for chronic heart failure in children is effective in the patients with CHD. The efficacy does not depend on the morphological difference of the systemic ventricule, "right or left"
HEART FAILURE TREATMENT Aims: Abnormal renal function is associated with increased risk for cardiovascular morbidity and mortality. We studied the relationship between renal impairment and cardiac structure and function in patients with heart failure with preserved ejection fraction (HFpEF). Methods: The Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) study enrolled 301 patients with HF, LVEF ≥ 45%, and elevated NT-proBNP > 400 pg/ml (mean age 71 years, 56% female, 94% with hypertension, 38% diabetics). Urinary albumin to creatinine ratio (UACR) was <10 mg/g (normal) in 104 patients (41%), above 10mg/g yet less than microalbuminuria level (intermediate range) in 19%, and in microalbuminuria range or greater (≥17 mg/g for men, ≥25 mg/g for women) in 40%. Mean eGFR was 65.4±20.4 ml/min/1.73m 2 . Results: In multivariate analysis patients with albuminuria had higher E/E' (p =0.030), greater LAVi (p=0.013), and higher values of NTproBNP (p<0.0001), even in patients with intermediate UACR (p=0.014). Lower eGFR was associated with lower E' (p=0.035), higher relative wall thickness (RWT) (p=0.022), and elevated NT-proBNP (p =0.041). 
